Announcement no. 9/2008
To the OMX Nordic Exchange Copenhagen Copenhagen,
May 13, 2008
Announcement on rumours
Summary: Discussion of potential transactions with various companies
With reference to an article in Børsen today concerning a potential transaction
with Zealand Pharma A/S, Curalogic can confirm that the company has had
discussions with Zealand Pharma A/S about a potential transaction but that these
discussions are no longer active.
Curalogic is currently in discussions with a number of companies about different
potential transactions in line with the strategy for the company, but none of
these discussions have reached a point where Curalogic is able to provide
further information about details of the discussions or evaluate the probability
that Curalogic and one of these parties will reach an agreement.
Yours sincerely,
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO, Phone +45 99 99 24 01
Helle Busck Fensvig, EVP and CFO, Phone +45 99 99 24 03
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic
Exchange Copenhagen (CUR.CO) as a SmallCap+ company. Curalogic has ample cash
resources and has demonstrated its ability to conduct complex clinical studies
with a small group of development experts. Curalogic has initiated a search
process to identify development projects offering an attractive risk profile.
Curalogic expects to conclude an agreement during 2008 that will secure future
clinical development projects for the Company.
This announcement contains forward-looking statements regarding the Company's
future financial development and performance and other statements which are not
historical facts. Such statements are made on the basis of assumptions and
expectations which, to the best of the Company's knowledge and belief, are
reasonable, at this time, but may prove to be erroneous in the future.
